Incremental Value of CSF Biomarkers in Clinically Diagnosed AD and Non-AD Dementia

Background: Cerebrospinal fluid (CSF) biomarkers are used to diagnose Alzheimer disease (AD), especially in atypical clinical presentations. No consensus currently exists regarding cut-off values. This study aimed, firstly, to define optimal cut-off values for CSF biomarkers, and secondly, to invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Oudart, Jean-Baptiste, Djerada, Zoubir, Nonnonhou, Vignon, Badr, Sarah, Bertholon, Laurie-Anne, Dammak, Anis, Jaidi, Yacine, Novella, Jean-Luc, Pallet, Nicolas, Gillery, Philippe, Mahmoudi, Rachid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330115/
https://www.ncbi.nlm.nih.gov/pubmed/32670183
http://dx.doi.org/10.3389/fneur.2020.00560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330115/
https://www.ncbi.nlm.nih.gov/pubmed/32670183
http://dx.doi.org/10.3389/fneur.2020.00560

Ejemplares similares